Antibody Production
Custom production of Fab, scFv, VHH and bispecific fragments, optimising tissue penetration and production timelines.
SanjingBio brings deep experience in recombinant antibody expression. Beyond routine full-length antibodies, we take on diverse and demanding antibody fragments and engineered formats.
Whether single-chain antibodies (scFv), antigen-binding fragments (Fab), nanobodies (VHH), or the structurally harder antibody fusion proteins, IgG-scFv, tandem scFv and multivalent VHH, our optimised HEK293/CHO transient and efficient cell-free platforms deliver precise production at high yield and activity.
The solution runs from sequence to purified sample: supply the gene sequence and our senior team and platforms handle synthesis, expression and purification throughout, so the final product matches your specification and quality expectations exactly.
Enquire now →
Covering scFv, Fab, VHH and antibody fusion proteins to meet complex structural and functional requirements.
Human, mouse, rat, rabbit, dog and non-human primate formats, with cross-species sequence optimisation and efficient expression.
The team brings more than ten years of antibody fragment development and production experience, with dependable processes and stable delivery.
HEK293, CHO and cell-free platforms can be chosen as needed to optimise expression efficiency and turnaround.
Six stages. Supply just the gene sequence — synthesis, expression and purification are handled end to end by the senior team; outputs and acceptance criteria are in the specifications below.
Antibody fragment genes are synthesized and sequence-verified
Mammalian or cell-free expression constructs are built for the fragment format
Transient HEK293/CHO or cell-free expression at high yield and activity
Affinity chromatography to ≥95% purity
QC including SDS-PAGE confirms fragment structure and purity
Purified fragment sample and sequencing report delivered
Gene synthesis through purified delivery totals roughly 5–7 weeks; the platform is chosen per fragment among HEK293, CHO and cell-free systems.
Beyond routine scFv, Fab and VHH, we take on structurally demanding antibody fusion proteins, IgG-scFv, tandem scFv and multivalent VHH — produced at high yield and activity on our optimised HEK293/CHO transient and efficient cell-free platforms.
Deliverables, acceptance criteria and timelines by experimental stage. The staging differs from the process above: the process shows how a project runs, while this table is the acceptance basis written into the contract.
| Stage | Scope | Deliverables | Standards | Timeline |
|---|---|---|---|---|
| Gene synthesis & cloning | Sequence synthesis and vector construction | Sequencing report | Sequence verified | 2–3 weeks |
| Large-scale recombinant antibody expression | Transient expression and purification | Purified antibody sample | Purity ≥95% | 3–4 weeks |
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
